Theralase(R) Extends Warrants
Theralase Technologies (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on light, radiation, sound and drug-activated therapeutics for treating cancer, bacteria and viruses, has announced plans to extend its warrant expiration date. The company aims to extend 1,840,000 share purchase warrants from September 7th, 2025 to September 7th, 2028.
These warrants, originally issued on September 7th, 2023 through a private placement, are exercisable at CAN $0.35 per share. The extension is pending final approval from the TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF), società farmaceutica in fase clinica specializzata in terapie attivate da luce, radiazioni, suono e farmaci per il trattamento di cancro, batteri e virus, ha annunciato l'intenzione di prorogare la scadenza dei suoi warrant. La società intende estendere la validità di 1.840.000 warrant per l'acquisto di azioni dalla data del 7 settembre 2025 al 7 settembre 2028.
I warrant, originariamente emessi il 7 settembre 2023 tramite un collocamento privato, sono esercitabili a CAN $0.35 per azione. L'estensione è subordinata all'approvazione finale della TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF), una compañía farmacéutica en fase clínica centrada en terapias activadas por luz, radiación, sonido y fármacos para tratar cáncer, bacterias y virus, ha anunciado su plan de prorrogar la fecha de vencimiento de sus warrants. La empresa pretende extender 1.840.000 warrants para compra de acciones del 7 de septiembre de 2025 al 7 de septiembre de 2028.
Estos warrants, emitidos originalmente el 7 de septiembre de 2023 mediante una colocación privada, son ejercitables a CAN $0.35 por acción. La prórroga está pendiente de la aprobación final de la TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF)는 암, 박테리아 및 바이러스를 치료하기 위한 빛, 방사선, 음향 및 약물 활성화 치료법에 중점을 둔 임상 단계 제약회사로서 워런트 만기 연장 계획을 발표했습니다. 회사는 1,840,000주 매수 워런트의 만기를 2025년 9월 7일에서 2028년 9월 7일로 연장하려고 합니다.
이 워런트들은 2023년 9월 7일 사모 발행으로 최초 발행되었으며, 주당 CAN $0.35에 행사할 수 있습니다. 연장은 TSX 벤처 거래소의 최종 승인을 기다리고 있습니다.
Theralase Technologies (OTCQB: TLTFF), une société pharmaceutique en phase clinique spécialisée dans les thérapies activées par la lumière, les radiations, le son et les médicaments pour traiter le cancer, les bactéries et les virus, a annoncé son intention de prolonger la date d'expiration de ses warrants. La société vise à étendre la durée de 1 840 000 warrants d'achat d'actions du 7 septembre 2025 au 7 septembre 2028.
Ces warrants, initialement émis le 7 septembre 2023 via un placement privé, sont exerçables à CAN $0.35 par action. La prolongation est soumise à l'approbation finale de la TSX Venture Exchange.
Theralase Technologies (OTCQB: TLTFF), ein pharmazeutisches Unternehmen in der klinischen Phase, das sich auf licht-, strahlen-, schall- und arzneimittelaktivierte Therapien zur Behandlung von Krebs, Bakterien und Viren spezialisiert hat, hat Pläne angekündigt, das Ablaufdatum seiner Warrants zu verlängern. Das Unternehmen beabsichtigt, die Laufzeit von 1.840.000 Aktienkauf-Warrants vom 7. September 2025 auf den 7. September 2028 zu verlängern.
Diese Warrants, ursprünglich am 7. September 2023 durch eine Privatplatzierung ausgegeben, sind zu CAN $0.35 pro Aktie ausübbar. Die Verlängerung steht unter dem Vorbehalt der endgültigen Genehmigung durch die TSX Venture Exchange.
- None.
- Delays potential warrant exercise proceeds for the company
- Extension suggests current share price may be below warrant exercise price
Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 1,840,000 share purchase warrants ("Warrants") expiring September 7th, 2025 to September 7th, 2028.
The Warrants were issued on September 7th, 2023, pursuant to a private placement involving the issuance of 1,840,000 units of the Company. The Warrants are exercisable at $CAN 0.35 per share. All other terms and conditions of the Warrants will remain unchanged. The Warrant expiry date extension is subject to final acceptance by the TSX Venture Exchange.
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264389
FAQ
What is the new expiration date for Theralase (TLTFF) warrants?
How many warrants are affected by Theralase's extension announcement?
What is the exercise price for Theralase's extended warrants?
When were the original Theralase (TLTFF) warrants issued?
What type of company is Theralase Technologies (TLTFF)?
